Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and STACY MOULDER.
FUNDA MERIC-BERNSTAM
Connection Strength
1.104
STACY MOULDER
  1. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.
    View in: PubMed
    Score: 0.160
  2. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
    View in: PubMed
    Score: 0.145
  3. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373.
    View in: PubMed
    Score: 0.142
  4. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience. 2016; 3(5-6):164-72.
    View in: PubMed
    Score: 0.138
  5. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
    View in: PubMed
    Score: 0.132
  6. NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression. Nat Commun. 2024 Dec 30; 15(1):10737.
    View in: PubMed
    Score: 0.062
  7. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open. 2021 10; 6(5):100230.
    View in: PubMed
    Score: 0.049
  8. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol. 2018 06 01; 29(6):1445-1453.
    View in: PubMed
    Score: 0.039
  9. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2015; 2(6):576-80.
    View in: PubMed
    Score: 0.032
  10. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. 2015 May 30; 6(15):12890-908.
    View in: PubMed
    Score: 0.032
  11. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53.
    View in: PubMed
    Score: 0.031
  12. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.
    View in: PubMed
    Score: 0.031
  13. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 2014 Dec; 14(6):468-74.
    View in: PubMed
    Score: 0.030
  14. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54.
    View in: PubMed
    Score: 0.030
  15. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84.
    View in: PubMed
    Score: 0.029
  16. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009 Dec; 20(12):1953-8.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.